Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean
The deal gives 14 countries a new purchasing route for the twice-yearly HIV prevention drug as new infections rose 13% from 2010 to 2024, Gilead said.
- On Tuesday, Gilead Sciences reached an agreement with the Pan American Health Organization to expand access to its HIV prevention drug Yeztugo across Latin America and the Caribbean.
- New HIV infections in Latin America and the Caribbean rose 13% between 2010 and 2024, driving the need to address gaps in utilization of prevention medicines.
- The agreement creates a new procurement pathway through PAHO for 14 countries including Brazil, Mexico, and Argentina that were not covered by Gilead's voluntary generic licensing deals.
- PAHO Director Jarbas Barbosa said the initiative gives countries another HIV prevention option, while Gilead is discussing possible local production of Yeztugo with Brazil's Health Ministry.
- Gilead has forecast $1 billion in sales for the long-acting drug in 2026, though actual availability depends on country-specific regulatory approvals and individual government decisions.
13 Articles
13 Articles
Clarin
Hola NewsGilead and PAHO seal an agreement to facilitate access to a key drug in HIV prevention in Latin America and the Caribbean.The initiative seeks to reduce new infections and improve access to preventive treatments, with support from local production in Brazil.
Drug, called Sunlenca commercially, is an injectable drug only applied twice a year. AP via Business Wire The Pan-American Health Organization (PAHO) will expand access to lenacapavir for HIV prevention in Latin America and the Caribbean. 我Lenacapavir is an injectable drug that works as an additional option for pre-exposure HIV (PrEP) prophylaxis, an effective and long-term alternative to oral pills. Through a new agreement with Gilead Sciences,…
Fourteen countries in Latin America are gaining access to lenacapavir, a long-acting HIV prevention drug administered by injection only twice a year, through the Pan American Health Organization (PAHO). PAHO has entered into an agreement with pharmaceutical ... for this purpose.
Gilead, PAHO agree to expedite lenacapavir access for HIV prevention
The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries, including Argentina, The post Gilead and PAHO agree to expedite lenacapavir access for HIV prevention appeared first on Pharmaceutical Business review.
Coverage Details
Bias Distribution
- 60% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
